Genco Shipping (GNK) Corporate Presentation from NobleCon18Research, News and Market Data on Genco ShippingNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


6/2/2026
Consumer
Release – Vince Announces Reporting Date for First Quarter 2026 Financial Results
Vince Holding Corp., (Nasdaq: VNCE) (“VNCE” or the “Company”), a global retail platform, today announced that it plans to report its first quarter 2026 financial results pre-market on Tuesday, June...
2 min read
‌


6/2/2026
Media and Entertainment
Release – Snail Games Celebrates ARK’s Continued Expansion 11 Years After Launch
Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today celebrates the 11-year anniversary of the ARK franchise, highlighting...
5 min read
‌


6/2/2026
Media and Entertainment
Release – Alliance Home Entertainment Scores Exclusive North American Physical & U.S. EST Rights to Heated Rivalry
Alliance Entertainment Holding Corporation (Nasdaq: AENT), a leading distributor and omnichannel fulfillment partner to the entertainment and pop-culture collectibles industry, today announced that its Alliance Home Entertainment division has secured...
7 min read
‌


6/2/2026
Health
Release – Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced positive results from CRDF-004, a randomized, controlled, dose-finding Phase 2 clinical...
8 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.